Literature DB >> 9336021

Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension.

M McIntyre1, S E Caffe, R A Michalak, J L Reid.   

Abstract

Losartan potassium, an angiotensin II receptor antagonist, is the first of a new class of agents to be introduced for the treatment of hypertension. In this review, we describe the clinical pharmacology of losartan, including its pharmacokinetics in healthy, male volunteers and special patient groups, such as the elderly, patients with liver disease and patients with renal impairment. We also review its pharmacodynamics, including safety and tolerability; specificity of action; and the effect of salt depletion. We then review the studies examining clinical efficacy and safety in hypertension.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9336021     DOI: 10.1016/s0163-7258(97)82002-5

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  16 in total

1.  Pharmacokinetics of Losartan and its Active Metabolite EXP3174 in Healthy Iranian Subjects.

Authors:  Hossein Amini; Abolhassan Ahmadiani; Maryam Moazenzadeh
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

2.  The Angiotensin Receptor Blocker Losartan Suppresses Growth of Pulmonary Metastases via AT1R-Independent Inhibition of CCR2 Signaling and Monocyte Recruitment.

Authors:  Daniel P Regan; Jonathan W Coy; Kirti Kandhwal Chahal; Lyndah Chow; Jade N Kurihara; Amanda M Guth; Irina Kufareva; Steven W Dow
Journal:  J Immunol       Date:  2019-04-10       Impact factor: 5.422

3.  A study on the efficacy and safety of losartan in elderly patients with mild to moderate essential hypertension.

Authors:  F Fernández-Vega; J Abellan; S Sanz de Castro; J M Cucalón; B Maceira; A Gómez de la Cámara
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

Review 4.  Comparative safety and tolerability of angiotensin II receptor antagonists.

Authors:  L Mazzolai; M Burnier
Journal:  Drug Saf       Date:  1999-07       Impact factor: 5.606

5.  Spectrum of use for the angiotensin-receptor blocking drugs.

Authors:  M E Fabiani; C I Johnston
Journal:  Curr Hypertens Rep       Date:  1999-10       Impact factor: 5.369

Review 6.  Clinical pharmacokinetics of losartan.

Authors:  Domenic A Sica; Todd W B Gehr; Siddhartha Ghosh
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

7.  Angiotensin II, independent of plasma renin activity, contributes to the hypertension of autonomic failure.

Authors:  Amy C Arnold; Luis E Okamoto; Alfredo Gamboa; Cyndya Shibao; Satish R Raj; David Robertson; Italo Biaggioni
Journal:  Hypertension       Date:  2012-12-24       Impact factor: 10.190

8.  Safety and efficacy of fimasartan in patients with arterial hypertension (Safe-KanArb study): an open-label observational study.

Authors:  Jeong Bae Park; Ki-Chul Sung; Seok-Min Kang; Eun Joo Cho
Journal:  Am J Cardiovasc Drugs       Date:  2013-02       Impact factor: 3.571

9.  Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics.

Authors:  David Gurwitz
Journal:  Drug Dev Res       Date:  2020-03-04       Impact factor: 5.004

10.  Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements.

Authors:  Joel M Neutel; William J Elliott; Joseph L Izzo; Chao L Chen; Harvey N Masonson
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Sep-Oct       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.